AVANIR Pharmaceuticals to Announce First Fiscal Quarter 2003 Results on February 12

SAN DIEGO, Feb 7, 2003 /PRNewswire-FirstCall via COMTEX/ -- AVANIR Pharmaceuticals (Amex: AVN) will announce financial results for the first fiscal quarter of 2003 ended December 31, 2002 on Wednesday, February 12, 2003.

Following the release, management will host a conference call with a simultaneous webcast at 11:00 a.m. Pacific/ 2:00 p.m. Eastern to discuss first fiscal quarter 2003 operating performance and outlook. The webcast, featuring President and Chief Executive Officer Gerald J. Yakatan, Ph.D. and Vice President and Chief Financial Officer Gregory Hanson, will be available live via the Internet by accessing AVANIR's web site at www.avanir.com . The live webcast will also be available at CCBN's www.companyboardroom.com . Please go to either web site at least ten minutes early to register, download and install any necessary audio software.

For those who cannot listen to the live broadcast, the online replays will be available for 90 days, or a phone replay will be available through February 19, 2003 by dialing (888) 266-2086 or 703-925-2435 and entering the passcode # 6412665.

AVANIR Pharmaceuticals, based in San Diego, is engaged in research, discovery and development of innovative drug products for chronic diseases and, through its subsidiary Xenerex Biosciences, antibody generation services. Further information about AVANIR and Xenerex can be found at www.avanir.com .

AVANIR press releases, including any forward-looking statements contained therein, should be reviewed in conjunction with the company's Annual Report on Form 10-K and other publicly available information regarding the company. Copies of such information are available from the company upon request. Such publicly available information sets forth many risks and uncertainties related to the company's business and technology. Forward-looking statements often contain such words like "estimate," "anticipate," "believe," "plan" or "expect." Research findings are not always supportable by evidence obtained from subsequent clinical trials. Final review decisions made by the FDA and other regulatory agencies concerning clinical trial results are unpredictable and outside the influence and/or control of the company.

For further information please contact: Kristen McNally, General Information, +1-310-407-6548, kmcnally@webershandwick.com, or Tricia Ross, Analyst/Investors, +1-310-407-6540, tross@webershandwick.com, or Tim Grace, Media, +1-312-640-6667, tgrace@webershandwick.com, all of FRB | Weber Shandwick, for AVANIR Pharmaceuticals; or Patrice Saxon, Investor Relations of AVANIR Pharmaceuticals, +1-858-622-5202, psaxon@avanir.com

SOURCE AVANIR Pharmaceuticals

CONTACT:
Kristen McNally, General Information, +1-310-407-6548,
kmcnally@webershandwick.com, or Tricia Ross, Analyst/Investors,
+1-310-407-6540, tross@webershandwick.com, or Tim Grace, Media,
+1-312-640-6667, tgrace@webershandwick.com, all of FRB | Weber Shandwick, for
AVANIR Pharmaceuticals; or Patrice Saxon, Investor Relations of AVANIR
Pharmaceuticals, +1-858-622-5202, psaxon@avanir.com
/Company News On-Call: http://www.prnewswire.com/comp/509050.html

URL:
http://www.avanir.com

Copyright (C) 2003 PR Newswire. All rights reserved.